Clinical studies on patients with NAFLD have demonstrated that statins have a positive impact by diminishing steatosis, NASH, and fibrosis, although the presence of the PNPLA3 genetic variant blunted these beneficial effects.43 Here, PNPLA3 is linked to metabolic dysfunction-associated steatotic liver disease.